Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05111301 · ClinicalTrials.gov registry record · NA
Control-IQ Technology in Individuals With Type 2 Diabetes
A NA study of Type 2 Diabetes Treated With Insulin, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05111301 is a NA study of Type 2 Diabetes Treated With Insulin that has completed, run by Tandem Diabetes Care. The registered enrollment target is 30 participants, below the 299-participant average among 3 other Type 2 Diabetes Treated With Insulin trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05111301, a NA study of Type 2 Diabetes Treated With Insulin, has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
Conditions Studied
Interventions
- DEVICE Control-IQ technology 1.5
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
New York
- Icahn School of Medicine at Mt. Sinai - New York
Texas
- Texas Diabetes and Endocrinology - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2022-08-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05111301
The ClinicalTrials.gov registry entry for NCT05111301 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 299-participant average among 3 other Type 2 Diabetes Treated With Insulin trials with a reported enrollment target (90% lower). The listed sponsor is Tandem Diabetes Care, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Treated With Insulin appearing as the primary indexed condition, and to 1 intervention - of which Control-IQ technology 1.5 is the first listed.
NCT05111301 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT05111301 about?
NCT05111301 is a clinical study titled "Control-IQ Technology in Individuals With Type 2 Diabetes". A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
What is the current status of trial NCT05111301?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-11-30. Estimated completion is 2022-08-18.
What conditions does trial NCT05111301 study?
This clinical trial studies the following conditions: Type 2 Diabetes Treated With Insulin.
What interventions are being tested in trial NCT05111301?
The interventions under investigation include: Control-IQ technology 1.5 (DEVICE).
Who is sponsoring clinical trial NCT05111301?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05111301 being conducted?
This trial has 3 study locations across Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Treated With Insulin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.